Skip to main content
PROK
NASDAQ Life Sciences

ProKidney Reports Q1 Results, Confirms Phase 3 Enrollment On Track, $225M Cash Runway

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.605
Mkt Cap
$484.648M
52W Low
$0.54
52W High
$7.13
52W Position info
197% above low
Off High info
77% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

PROK has more than doubled off its 52-week low of $0.54.

Summary

ProKidney reported first-quarter 2026 financial results, showing cash, cash equivalents, and marketable securities of $224.9 million as of March 31, 2026, down from $270.0 million at year-end 2025. The company projects this liquidity will fund operations into mid-2027. Research and development expenses increased to $33.8 million, primarily due to the ongoing PROACT 1 study, leading to an increased net loss of $42.6 million. On the clinical front, the company reiterated that Phase 3 PROACT 1 enrollment for the surrogate endpoint is on track for completion in mid-2026, with pivotal topline results expected in Q2 2027. This report confirms the previously established FDA alignment on the accelerated approval pathway for rilparencel, as noted in the full-year 2025 results. For a clinical-stage biotech, maintaining a sufficient cash runway and hitting clinical milestones are critical, making this a material update for investors to track.

At the time of this announcement, PROK was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $484.6M. The 52-week trading range was $0.54 to $7.13. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

PROK - Latest Insights

PROK
Nov 12, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $1.04 info
Change: -$0.109 (-9%) info
Market Cap: $316.665M info
PROK
Nov 12, 2026, 4:10 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.15
Real-time Price: $1.04 info
Change: -$0.109 (-9%) info
Market Cap: $316.665M info
PROK
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $1.04 info
Change: -$0.099 (-9%) info
Market Cap: $316.665M info
PROK
Oct 29, 2026, 4:46 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.46
Real-time Price: $1.04 info
Change: -$0.419 (-29%) info
Market Cap: $316.665M info
PROK
Aug 10, 2026, 4:22 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.64
Real-time Price: $1.04 info
Change: -$0.599 (-37%) info
Market Cap: $316.665M info